Breast Cancer Clinical Trials in Houston

Showing 361-380 of 568 trials

COMPLETEDPhase 2< 1 mile

Neoadjuvant GW572016 to Treat Breast Cancer

NCT00206427

We want to learn whether GW572016 is effective in breast cancers that have HER2.

Breast Cancer

Baylor Breast Care Center49 participantsStarted Aug 2004

Los Angeles, California, United States • Albuquerque, New Mexico, United States • Houston, Texas, United States

TERMINATEDPhase 3< 1 mile

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.

Breast Cancer

Amgen4,509 participantsStarted Jun 2010

Birmingham, Alabama, United States • Tucson, Arizona, United States • Jonesboro, Arkansas, United States +456 more locations

Neoadjuvant GW572016 to Treat Breast Cancer

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Breast Cancer Trials in Other Cities

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Breast Mesh Used in Two-staged Breast Reconstruction

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Development of a Patient Decision Aid for Women Considering Breast Reconstruction

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Other Conditions in Houston